Sagimet Biosciences (SGMT) Shares Outstanding (Diluted Average) (2022 - 2026)
Sagimet Biosciences (SGMT) recorded quarterly Shares Outstanding (Diluted Average) of $32.6 million in Q1 2026, up 0.66% quarter-over-quarter from $32.3 million in Q4 2025, and up 1.13% on a YoY basis from $32.2 million in Q1 2025.
Sagimet Biosciences (SGMT) Shares Outstanding (Diluted Average) (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Shares Outstanding (Diluted Average) history runs 5 years deep, the most recent figure standing at $32.6 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 1.13% year-over-year to $32.6 million; the TTM figure through Mar 2026 stood at $32.6 million (up 1.13% YoY), while the FY2025 annual figure was $32.3 million, up 3.17% from the prior year.
- Shares Outstanding (Diluted Average) was $32.6 million for Q1 2026 at Sagimet Biosciences, up from $32.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $32.6 million in Q1 2026 to a low of $184589.0 in Q2 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $19.7 million across 5 years, with a median of $30.0 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) surged 16739.32% in 2024, then advanced 0.88% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $184619.0 in 2022, then surged by 5565.9% to $10.5 million in 2023, then jumped by 199.71% to $31.4 million in 2024, then increased by 3.17% to $32.3 million in 2025, then advanced by 0.66% to $32.6 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $32.6 million (Q1 2026), $32.3 million (Q4 2025), and $32.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 92.44 Mn |
| 10 | Sagimet Biosciences | 211.96 Mn | 211.96 Mn | - | 32.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.56 Mn |
| Dec 31, 2025 | 32.35 Mn |
| Sep 30, 2025 | 32.46 Mn |
| Jun 30, 2025 | 32.20 Mn |
| Mar 31, 2025 | 32.20 Mn |
| Dec 31, 2024 | 31.35 Mn |
| Sep 30, 2024 | 31.04 Mn |
| Jun 30, 2024 | 31.91 Mn |
| Mar 31, 2024 | 29.04 Mn |
| Dec 31, 2023 | 10.46 Mn |
| Sep 30, 2023 | 18.19 Mn |
| Jun 30, 2023 | 189,520.00 |
| Mar 31, 2023 | 185,137.00 |
| Dec 31, 2022 | 184,619.00 |
| Sep 30, 2022 | 185,084.00 |
| Jun 30, 2022 | 184,589.00 |